The equine herpesvirus 1 vaccine helps protect horses from respiratory disease, neurological complications, and abortion linked to EHV-1 infection. Vaccination is a key part of biosecurity and herd health programs on breeding farms, competition premises, and equine boarding facilities.
Below is a structured overview of common product characteristics, label claims, and regional availability to help veterinarians and owners compare options quickly.
| Vaccine Type | Key Label Indications | Storage Requirements | Typical Booster Guidance |
|---|---|---|---|
| Killed (Inactivated) | Respiratory disease reduction; may include abortion claims depending on label | 2–8°C, do not freeze | Initial series, then every 4–6 months for high-risk groups |
| Modified Live Virus (MLV) | Respiratory protection; some products target abortion with expert guidance | −15 to −25°C for stability once reconstituted | Annual or semiannual based on risk and regulatory approval |
| Recombinant Vector | Respirory aid, may enhance immune response in competition horses | 2–8°C | Annual revaccination, often used with core inactivated boosters |
| Pregnant Mare Formulation | Abortion reduction due to EHV-1; specific timing protocols required | 2–8°C | Booters typically at 5, 7, and 9 months of gestation per label |
Vaccine Types and Immunological Mechanisms
Understanding the difference between killed and modified live vaccines helps tailor protocols for individual horses. Killed EHV-1 products generally have a well-established safety profile and are widely used in broodmare and geriatric populations. Modified live vaccines can stimulate stronger and longer cellular immunity but may carry additional contraindications in immune-compromised or pregnant animals.
Recombinant platforms offer an alternative for horses that need respiratory protection without repeated inactivated boosters. These products often require a priming series and annual boosters to maintain antibody levels suitable for competition yards and breeding operations.
Recommended Vaccination Schedules
For adult horses at low risk of commingling, annual revaccination with an inactivated product is often sufficient. Broodmares follow a gestational schedule designed to maximize antibody transfer to the foal, while show horses may require more frequent dosing to satisfy event entry rules.
Initial series in naïve horses usually involve two to three doses, spaced four to six weeks apart, followed by a booster at six months. Foals from vaccinated maternals may need an earlier starter series to align with waning maternal antibodies.
Contraindications and Risk Management
Animals with a history of vaccine reactions, hypersensitivity to neomycin or polymyxin B, or acute febrile illness should be evaluated carefully before EHV-1 vaccination. Veterinary consultation helps balance individual risk against exposure potential at shows, sales, and breeding facilities.
Proper aseptic technique, site rotation, and post-vaccination observation minimize local and systemic adverse events. Facilities with recent EHM cases may require stricter protocols, including serologic monitoring and temporary competition deferrals per regulatory guidance.
Regional Labeling and Regulatory Differences
Product approvals and indications vary by country, and some labels include only respiratory claims while others specify abortion risk reduction. Importers and practitioners must verify local registration status and comply with movement restrictions when transporting vaccinated animals across jurisdictions.
Official certification for Equine Influenza or EHV may be required for certain events, and documentation of product, batch, and administration details supports traceability. Regular communication with state veterinarians ensures alignment with emerging outbreaks and import requirements.
Key Takeaways and Practical Recommendations
- Match vaccine type to horse risk profile: inactivated for broodmares and geriatric animals, modified live or recombinant for low-risk, non-pregnant performance horses.
- Adhere strictly to label intervals and gestational schedules to optimize antibody transfer and minimize adverse events.
- Maintain detailed vaccination records including product, lot number, and administration date for event entry and regulatory compliance.
- Implement biosecurity measures such as isolation, testing, and traffic control during outbreaks, regardless of vaccination status.
- Consult your veterinarian when integrating EHV-1 vaccination with other immunizations or ahead of travel to high-risk venues.
FAQ
Reader questions
How long after EHV-1 vaccination does protective immunity develop?
Protective immunity typically begins to develop within two to four weeks after the final dose in a primary series, with maximal antibody responses often seen at four to six weeks. Modified live products may induce faster cellular responses, but full protection in high-risk settings usually requires adherence to booster intervals.
Can pregnant mares be vaccinated without risk to the fetus?
Pregnant mares can be vaccinated safely when products with appropriate gestational labeling are used and administration follows the recommended schedule, commonly at months 5, 7, and 9. Using off-label products or incorrect timing may elevate fetal risk, so veterinary oversight is essential.
What should I do if my horse experiences mild swelling at the injection site after EHV-1 vaccination?
Most local swellings resolve within days with cold compresses and gentle exercise. If swelling increases, persists beyond 48 hours, or is accompanied by systemic signs such as fever, contact your veterinarian promptly to rule out abscess or hypersensitivity reaction. Many event organizers require vaccination within the preceding six months, though some may mandate a booster within four months. Owners should confirm specific rules for each show or facility and maintain accurate records of product name, lot, and administration date for compliance.